nefazodone has been researched along with paroxetine in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (29.79) | 18.2507 |
| 2000's | 19 (40.43) | 29.6817 |
| 2010's | 14 (29.79) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carlier, PR; Lo, MM; Lo, PC; Reynolds, IJ; Richelson, E; Sharma, TA; Tatsumi, M | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Cleves, AE; Jain, AN; Kirshner, D; Langham, JJ; Spitzer, R | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Jung, ME; Kang, SY; Kim, HJ; Kim, J; Kim, MJ; Kim, MS; Lee, J; Lee, KN; Lee, M; Lee, SH; Park, EJ; Park, WK; Seo, HJ; Son, EJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Preskorn, SH | 1 |
| Abed, RT; Ascher, A; Baldwin, DS; Buckingham, SA; Cox, J; Hawley, CJ; Maragakis, BP; Pover, GH | 1 |
| Attenburrow, ME; Cowen, PJ; Pearson, G; Sargent, P; Sharpley, AL; Williamson, DJ | 1 |
| Bryant, SG | 1 |
| Castañeda, R; Levy, R; Sussman, N; Westreich, LM | 1 |
| Blew, PG; John, L; Perreault, MM; Tao, T | 1 |
| Cowen, PJ; Odontiadis, J; Pearson, G; Sargent, P; Williamson, DJ | 1 |
| Peak, DA | 1 |
| Campo, JV; Perel, JM; Smith, C | 1 |
| Anand, VS; Dewan, MJ | 1 |
| Cho, R; Kapur, S; Kennedy, S; Meyer, JH | 1 |
| Farvolden, P; Mancini, C; Oakman, JM; Van Ameringen, M | 1 |
| Davidson, JR | 1 |
| Dunn, NR; Freemantle, SN; Mackay, FR; Mann, RD; Martin, RM; Pearce, GL | 1 |
| Court, MH; Duan, SX; Greenblatt, DJ; Hesse, LM; Shader, RI; Venkatakrishnan, K; von Moltke, LL | 1 |
| Olivier, B; Waldinger, MD; Zwinderman, AH | 1 |
| Baruch, Y; Chelben, J; Lustig, M; Strous, RD | 1 |
| Baldwin, DS; Hawley, CJ; Mellors, K | 1 |
| Argyropoulos, SV; Bell, CJ; Edwards, C; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Kenemans, JL; Trooster, S; van Laar, MW; van Megen, HJ; Verbaten, MN; Volkerts, ER | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ | 1 |
| Baker, B; Baldini-Rossi, N; Hollander, E; Pallanti, S; Sood, E | 1 |
| Blier, P; de Montigny, C; Debonnel, G; Hébert, C; Lavoie, N; Saint-André, E | 1 |
| Kelly, BD | 1 |
| Kalgutkar, AS; Obach, RS; Soglia, JR; Zhao, SX | 1 |
| Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, S | 1 |
| Aubry, JM; Bertschy, G; Bondolfi, G; Gex-Fabry, M; Kosel, M; Malafosse, A; Perroud, N; Uher, R | 1 |
| Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X | 1 |
7 review(s) available for nefazodone and paroxetine
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder; Drug Design; Drug Tolerance; Drugs, Investigational; Fluoxetine; Humans; Imipramine; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1995 |
Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome.
Topics: Anticonvulsants; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Fluoxetine; Follow-Up Studies; Humans; Monoamine Oxidase Inhibitors; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Stress Disorders, Post-Traumatic; Treatment Outcome; Triazoles | 2000 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Pharmacological treatments of pathological gambling.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Bupropion; Comorbidity; Disruptive, Impulse Control, and Conduct Disorders; Dose-Response Relationship, Drug; Fluvoxamine; Gambling; Humans; Naltrexone; Outcome Assessment, Health Care; Paroxetine; Piperazines; Research Design; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders; Triazoles | 2005 |
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2016 |
10 trial(s) available for nefazodone and paroxetine
| Article | Year |
|---|---|
A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Severity of Illness Index; Treatment Outcome; Triazoles | 1996 |
The effects of paroxetine and nefazodone on sleep: a placebo controlled trial.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Double-Blind Method; Electroencephalography; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polysomnography; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 1996 |
Effect of paroxetine and nefazodone on 5-HT1A receptor sensitivity.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Double-Blind Method; Humans; Hydrocortisone; Hypothermia; Male; Middle Aged; Paroxetine; Piperazines; Pyrimidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Receptor Agonists; Triazoles | 1997 |
Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Double-Blind Method; Ejaculation; Humans; Male; Middle Aged; Paroxetine; Piperazines; Placebos; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 2001 |
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment.
Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome; Triazoles | 2001 |
Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Depressive Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Outpatients; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sleep; Sleep, REM; Triazoles | 2002 |
Differential effects of amitriptyline, nefazodone and paroxetine on performance and brain indices of visual selective attention and working memory.
Topics: Adult; Amitriptyline; Antidepressive Agents; Attention; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Electrooculography; Evoked Potentials; Female; Humans; Male; Memory; Neuropsychological Tests; Paroxetine; Piperazines; Reaction Time; Task Performance and Analysis; Triazoles | 2002 |
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles | 2003 |
Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Blood Platelets; Blood Pressure; Cyclohexanols; Desipramine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Piperazines; Reference Values; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Time Factors; Triazoles; Tyramine; Venlafaxine Hydrochloride | 2007 |
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone.
Topics: Adult; Affect; Algorithms; Antidepressive Agents, Second-Generation; Delta Rhythm; Depressive Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Monitoring, Ambulatory; Paroxetine; Piperazines; Signal Processing, Computer-Assisted; Sleep; Sleep, REM; Treatment Outcome; Triazoles | 2009 |
31 other study(ies) available for nefazodone and paroxetine
| Article | Year |
|---|---|
Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group.
Topics: Amino Alcohols; Animals; Antidepressive Agents; Dopamine; Humans; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Serotonin; Species Specificity | 1998 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physical binding pocket induction for affinity prediction.
Topics: Binding Sites; Ligands; Models, Molecular; Neural Networks, Computer; Peptide Fragments; Protein Binding; Receptor, Serotonin, 5-HT1A | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT(2A) receptor and 5-HT transporter.
Topics: Animals; Antidepressive Agents; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Mice; Motor Activity; Piperazines; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin 5-HT2 Receptor Antagonists; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Reassessment of nefazodone.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles | 1996 |
Drug craving and other negative reactions after abrupt substitution of nefazodone for other serotonergic agents.
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Piperazines; Recurrence; Serotonin Agents; Substance-Related Disorders; Triazoles; Venlafaxine Hydrochloride | 1996 |
Serotonin syndrome associated with nefazodone and paroxetine.
Topics: Antidepressive Agents, Second-Generation; Coma; Drug Synergism; Female; Humans; Hyponatremia; Middle Aged; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Syndrome; Triazoles | 1997 |
Toxic effects of nefazodone.
Topics: Antidepressive Agents, Second-Generation; Drug Interactions; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Serotonin; Syndrome; Triazoles | 1997 |
Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Drug Interactions; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Paroxetine; Piperazines; Tacrolimus; Triazoles | 1998 |
Evaluating the tolerability of the newer antidepressants.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Diseases; Citalopram; Cyclohexanols; Delayed-Action Preparations; Drug Information Services; Fluvoxamine; Gastrointestinal Diseases; Guidelines as Topic; Humans; Incidence; Paroxetine; Piperazines; Placebos; Selective Serotonin Reuptake Inhibitors; Sertraline; Sexual Dysfunctions, Psychological; Triazoles; United States; United States Agency for Healthcare Research and Quality; Venlafaxine Hydrochloride | 1999 |
The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET.
Topics: Adult; Analysis of Variance; Antidepressive Agents; Binding, Competitive; Female; Fluorine Radioisotopes; Humans; Male; Paroxetine; Piperazines; Pyrimidinones; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Tomography, Emission-Computed; Triazoles | 1999 |
Serotonergic agents in the treatment of social phobia in children and adolescents: a case series.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Female; Humans; Male; Paroxetine; Phobic Disorders; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Triazoles | 1999 |
Newer antidepressants: a comparison of tolerability in general practice.
Topics: Adult; Aged; Antidepressive Agents; Cohort Studies; Cyclohexanols; Depressive Disorder; Family Practice; Female; Fluoxetine; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Sertraline; Triazoles; Venlafaxine Hydrochloride | 1999 |
CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Topics: Antibodies; Antidepressive Agents, Second-Generation; Aryl Hydrocarbon Hydroxylases; Biotransformation; Bupropion; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Kinetics; Microsomes, Liver; Oxidoreductases, N-Demethylating; Paroxetine; Piperazines; Sertraline; Triazoles | 2000 |
Remission of SSRI-induced akathisia after switch to nefazodone.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Administration Schedule; Female; Fluoxetine; Humans; Paroxetine; Piperazines; Selective Serotonin Reuptake Inhibitors; Triazoles | 2001 |
Do new-generation antidepressants work?
Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Depression; Fluoxetine; Humans; Paroxetine; Piperazines; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride | 2008 |
Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose.
Topics: Acetaminophen; Binding Sites; Buspirone; Carbamazepine; Diclofenac; Diphenhydramine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hepatocytes; Humans; Indomethacin; Meloxicam; Microsomes, Liver; Molecular Structure; Paroxetine; Piperazines; Propranolol; Raloxifene Hydrochloride; Simvastatin; Structure-Activity Relationship; Thiazines; Thiazoles; Ticrynafen; Toxicity Tests; Triazoles | 2008 |
Clinical and genetic correlates of suicidal ideation during antidepressant treatment in a depressed outpatient sample.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clomipramine; Cyclohexanols; Depressive Disorder; Female; Genetic Association Studies; Humans; Male; Middle Aged; Paroxetine; Piperazines; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT1B; Severity of Illness Index; Suicidal Ideation; Tacrolimus Binding Proteins; Triazoles; Venlafaxine Hydrochloride; Young Adult | 2011 |